Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
PLK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN15714 | TAK-960 | 1137868-52-0 | TAK-960 is an investigational orally bioavailable potent and selective PLK1 inhibitor IC5015 nM that has shown activity in several tumor cell lines including those that express multidrug-resistant protein 1 MDR1 |
| CSN17496 | TAK-960 HCl | 2108449-45-0 | TAK-960 hydrochloride is an investigational orally bioavailable potent and selective PLK1 inhibitor IC5015 nM that has shown activity in several tumor cell lines including those that express multidrug-resistant protein 1 MDR1 |
| CSN16924 | SBE13 HCl | 1052532-15-6 | SBE13 HCl is a potent and selective PLK1 inhibitor with IC50 of 02 nM while 875 nM and 66 M for PLK3 and PLK2 SBE 13 could also induce cell cycle arrest reduce cell proliferation with EC50 of 5-60 M and induce apoptosis in a broad range of human cancer cell lines |
| CSN16422 | Ro 3280 | 1062243-51-9 | RO3280 is a potent highly selective inhibitor of Polo-like kinase 1 PLK1 with IC50 of 3 nM |
| CSN18787 | Rigosertib Sodium | 592542-60-4 | Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM |
| CSN15803 | Rigosertib Sodium (Random Configuration) | 1225497-78-8 | Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay It shows 30-fold greater selectivity against Plk2 and no activity to Plk3 |
| CSN18349 | Rigosertib | 592542-59-1 | Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM and shows 30-fold greater selectivity against PLK2 and no activity to PLK3 |
| CSN18210 | Poloxin | 321688-88-4 | Poloxin is a non-ATP competitive Polo-like Kinase 1 PLK1 inhibitor that targets the polo-box domain |
| CSN18009 | Poloxime | 17302-61-3 | Poloxime is an analogue of thymoquinone which bind to the phosphoserinephosphothreonine recognition site of the polo-box domain of polo-like kinase 1 |
| CSN16295 | NMS-1286937 | 1034616-18-6 | NMS-1286937 is an orally bioavailable small-molecule Polo-like kinase 1 PLK1 inhibitor IC502 nM with potential antineoplastic activity and no inhibition on PLK2 and PLK3 |
| CSN16314 | MLN0905 | 1228960-69-7 | MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM |
| CSN18151 | LFM-A13 | 244240-24-2 | LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 172 M and also inhibits PLK3 with IC50 of 72 M |
| CSN16519 | HMN-214 | 173529-46-9 | HMN-214 is a potent PLK1 inhibitor an average IC50 of 012 M and a prodrug of HMN-176 which alters the cellular spatial orientation of Plk1 |
| CSN19103 | HMN-176 | 173529-10-7 | HMN-176 is the active derivative of HMN-214 which can alter the cellular spatial orientation of Plk1 |
| CSN12710 | GW843682X | 660868-91-7 | GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 22 nM PLK1 and 91 nM PLK3 and displays 100-fold selectivity over 30 other kinases tested including cdk1 and cdk2 |
| CSN12716 | GSK461364 | 929095-18-1 | GSK461364 is a potent small molecule Polo-like kinase 1 PLK1 inhibitor with a Ki of 22 nM |
| CSN15736 | CFI-400945 | 1338806-73-7 | CFI400945 is a potent and selectiveorally bioavailable PLK4 inhibitor with an IC50 value of 28 14 nM have potential antineoplastic activity |
| CSN18037 | Centrinone-B | 1798871-31-4 | Centrinone-B is a high affinity and selective PLK4 inhibitor Ki 059 nM |
| CSN17208 | Centrinone | 1798871-30-3 | Centrinone is a selective and reversible inhibitor of polo-like kinase 4 Plk4 a serine-threonine protein kinase that initiates centriolecentrosome assembly |
| CSN12461 | BI-2536 | 755038-02-9 | BI-2536 is a potent Plk1 inhibitor with IC50 of 083 nM BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3 and also is a BRD4 inhibitor IC50 25 nM |
| CSN22785 | Cyclapolin 9 | 40533-25-3 | |
| CSN12712 | Volasertib | 755038-65-4 | |
| CSN23160 | TC-S 7005 | 1082739-92-1 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
